Jiangsu Nhwa Pharmaceutical (002262) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥1.61 billion, up 6.58% year-over-year, with net profit attributable to shareholders at ¥317.41 million, a 5.56% increase from the same period last year.

• Basic and diluted EPS were both ¥0.31, compared to ¥0.30 in Q1 2025.

• Total assets at quarter-end were ¥9.64 billion, up 4.55% from year-end 2025.

Financial highlights

• Operating cash flow dropped 50.57% year-over-year to ¥157.83 million, mainly due to increased cash payments related to operating activities.

• Gross margin improved as revenue growth outpaced cost increases.

• Investment income from wealth management products was ¥12.21 million, recognized as recurring due to its frequency and relevance to core operations.

• Non-recurring items had a net negative impact of ¥0.85 million on profit.

Outlook and guidance

• Management expects continued growth in core business, supported by increased prepayments for agency product procurement and higher contract liabilities.